TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
An international study reported 127 genetic loci associated with Alzheimer’s disease, including 48 not previously identified, using data from nearly 2.8 million people. The findings point to immune activity in microglia and changes in neurons, while the authors say estimates based on some genetic methods may understate inherited risk. Most participants were of European ancestry, limiting how precisely results apply across populations.
An international study using genetic data from nearly 2.8 million people identified 127 loci associated with Alzheimer’s disease, including 48 not previously reported, and found genetic signals linked to immune cells and neurons. The researchers also examined why earlier estimates based on common genetic variants may have captured only part of the inherited contribution to Alzheimer’s risk.
In a study published in Nature, the researchers combined data from 30 cohorts. The paper reports that these included 109,479 people diagnosed with Alzheimer’s, 74,141 proxy cases, 2,131,799 controls and 499,708 proxy controls. Proxy cases were people who reported that a parent had Alzheimer’s or dementia; they were not themselves included as diagnosed cases in that analysis. The paper gives an effective sample size of 416,493.
The researchers reported 118 significant loci in the multi-ancestry analysis and nine more in a European-ancestry-only analysis. The combined set contained 48 newly identified loci. The paper also describes prioritized genes and biological pathways, with results pointing to processes involving lipid binding, immune activation, amyloid breakdown and cell adhesion.
According to the paper, genetic associations were enriched in genes linked to microglia, the brain’s immune cells. Some neuronal gene-expression patterns were also associated with risk, although those findings weakened after adjustment for average differences in expression between cell types. The researchers identified candidate drug targets, but did not test them as treatments. The paper presents evidence about genetic associations and possible mechanisms, not proof that changing a particular gene or pathway will prevent or treat Alzheimer’s.
Why the Heritability Estimate Matters
The study’s authors compare twin-study estimates that 60% to 80% of susceptibility to Alzheimer’s is heritable with earlier analyses of common genetic variants, which suggested a much smaller share of disease liability. Their paper expands the genetic data and compares methods used to estimate how much risk is captured by measured variants. The authors suggest that the apparent gap may partly reflect the limits of particular estimation approaches, rather than a settled measure of how much genes matter.
That distinction matters for research into risk prediction and disease biology. A fuller map of genetic associations could help researchers identify pathways for further study and improve future prediction models. But the study does not establish an individual’s likelihood of developing Alzheimer’s, nor does it show that the newly identified loci can be used in clinical screening. Any predictive value must be tested in independent groups and across populations.
The findings also add to evidence that Alzheimer’s biology involves more than amyloid alone. Signals related to microglia, neurons and other pathways could broaden research questions, while offering no immediate change to clinical care. The candidate targets reported in the paper are leads for future work, not endorsed or proven therapies.
Products Worth Considering
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
Fitbit Sense Health & Fitness Smartwatch (White/Gold, International Version)
Fitbit Inspire 3 Health and Fitness Tracker Bundle
As an affiliate, we earn on qualifying purchases.
How the Study Expanded Earlier Genetics
The study describes earlier genome-wide association studies as identifying about 80 Alzheimer’s risk loci. It notes that estimates based on common single-nucleotide polymorphisms suggested those variants explained about 5% of disease liability, despite higher heritability estimates from twin research. Different methods capture different kinds of genetic information, so those figures are not directly interchangeable.
The paper says the new analysis included participants grouped by European, African, East Asian, admixed American and South Asian ancestry. However, about 91% of the effective sample was of European ancestry. The researchers note that ancestry-specific results were less precise in groups with smaller samples. The breadth of the study is therefore wider than a single-ancestry analysis, but its population coverage remains uneven.
The study describes Alzheimer’s as the most prevalent form of dementia. It also notes that current disease-modifying treatments primarily target amyloid-beta aggregates and have shown limited effectiveness in relieving symptoms. The genetic findings may help guide research into other mechanisms, but the study did not assess treatment effectiveness or change current treatment recommendations.
Limits of the Genetic Findings
The researchers report associations, not direct causes for every gene or pathway. They say it remains unclear whether the neuronal expression patterns seen in the analysis contribute to Alzheimer’s or arise as a consequence of neurodegeneration. After adjustment for average expression differences across cell types, the microglial association remained significant, while neuronal associations were only nominally significant. The paper reports that no individual microglial state reached statistical significance, even though inflammatory microglial states showed the strongest association.
The authors also identify ancestry imbalance as a limitation on how well the findings represent people from populations with smaller sample sizes. In addition, the paper’s candidate drug targets—including RRM2B, SYK, KEAP1, CACNA1S and AXL—were not tested as treatments in this study. The evidence described for those targets includes earlier experimental research, with mixed results; it does not establish that targeting them would benefit patients.
The researchers investigated whether existing methods may underestimate genetic contribution, but the paper does not establish a single heritability figure for Alzheimer’s. It does not provide a revised percentage that can replace earlier estimates, and the comparison depends on the method and data used.
Testing Risk Signals and Candidate Targets
The study’s authors say further research will need to test whether the newly identified loci and prioritized genes are linked to the disease through the proposed biological processes. The paper reports using independent clinical and biobank cohorts to evaluate prediction, but does not state a single performance figure or establish a clinically validated genetic test.
Future studies can also expand data from underrepresented ancestry groups to improve precision and assess whether risk signals hold across populations. For proposed drug targets, experimental and clinical research would be needed to establish safety and effectiveness; the current analysis itself did not test any intervention. Until those questions are addressed, the results are best treated as a research map of possible risk mechanisms rather than a change in patient care.
Key Questions
What did the Alzheimer’s genetics study find?
The study, published in Nature, identified 127 Alzheimer’s-associated genetic loci, including 48 not previously reported, and found associations involving microglia, neurons and several biological pathways. Genetic association does not by itself establish that a locus causes disease.
Does the study prove genes account for more than 80% of Alzheimer’s risk?
No. The study compares twin-study estimates of heritability at 60% to 80% with lower estimates from earlier analyses of common variants. It examines why methods may differ, but does not provide a new definitive percentage.
Could these findings change Alzheimer’s treatment now?
No treatment change follows directly from this study. The researchers identified candidate targets for further investigation, but did not test them as treatments or show that targeting them benefits patients.
How representative was the study across ancestries?
The study included five ancestry groupings, but about 91% of its effective sample was of European ancestry. The researchers report that results for groups with smaller samples were less precise, so more data are needed for stronger cross-population conclusions.
Source: news-medical.net
